

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF 7
04 APR -2 PM

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name AstraZeneca Pharmaceuticals LP			
2. Address <input type="checkbox"/> Check if different than previously reported 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437			
3. Principal Place of Business (if different from line 2) City: _____ State/zip (or Country) _____			
4. Contact Name Michele C. Campbell	Telephone (302) 885-1101	E-mail (optional)	5. Senate ID #
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 34975000

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ <small>Income (nearest \$20,000)</small>	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>800,000.00</u> <small>Expenses (nearest \$20,000)</small>
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate reporting accounting method. See instructions for description of options. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033(c) Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature *Michele C. Campbell* Date 02-13-09

Printed Name and Title Michele C. Campbell, Senior Counsel

Registrant Name AstraZeneca Pharmaceuticals LP Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 1 - Medicare Prescription Drug and Modernization Act of 2003.
 S. 1 - Prescription Drug and Medicare Improvement Act of 2003.

 Calls, letters and visits in support of a private sector, premium support approach to a Medicare drug benefit.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James P. Schlicht	Vice President, Government Affairs
Stephen D. McMillan	Director, Government Reimbursement
Jacqueline Pomfret	Senior Manager, Federal Government Affairs
Elise Deschenes	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Matthew C. Camp* Date 02-13-04

Printed Name and Title Michele C. Campbell, Senior Counsel

Form LD-2 (Rec. 4/03)

Page 2

Registrant Name AstraZeneca Pharmaceuticals LP Client Name _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cot information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

S. 1225 - Greater Access to Affordable Pharmaceuticals Act of 2003.
Calls and visits in opposition.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
James P. Schlicht	Vice President, Government Affairs
Stephen D. McMillan	Director, Government Reimbursement
Jacqueline Pomfret	Senior Manager, Federal Government Affairs
Elise Deschenes	Senior Manager, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 02-13-04

[Handwritten signature]

Printed Name and Title Michele C. Campbell, Senior Counsel

Form LD-2 (Rec. 4/03)

Page 5